Gastrooesophageal cancer
Not yet recruitingStudy of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy
Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy
- Disease:Gastrooesophageal cancer
- Substances:BemarituzumabIrinotecan+4
Germany- Participants:18–64 years · 65+ years
- Substances:Bemarituzumab
- Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH








